Research on the Classification and Evaluation Mechanism of High-Value Medical Consumables Medical Insurance Access

doi:10.19546/j.issn.1674-3830.2024.6.003

China Health Insurance ›› 2024, Vol. 0 ›› Issue (6) : 21-28. DOI: 10.19546/j.issn.1674-3830.2024.6.003

Author information +

History +

Abstract

High-value medical consumables have complex specifications and poor-quality evidence, which leads to high costs and difficulties in medical insurance access assessment. Establishing a classified assessment mechanism is the key to improving the efficiency of medical insurance access review. Based on the principle of medical insurance strategic purchasing, this paper divides high-value medical consumables into existing function, improved innovation, and complete innovation according to the criteria of market competition and patients' clinical benefits, and designs differentiated assessment methods, to provide a reference for the optimization of medical consumables list access management in China.

Key words

high-value medical consumable / medical insurance access / classified assessment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Research on the Classification and Evaluation Mechanism of High-Value Medical Consumables Medical Insurance Access[J]. China Health Insurance. 2024, 0(6): 21-28 https://doi.org/10.19546/j.issn.1674-3830.2024.6.003

References

[1] 丁锦希,黄新锋,李伟,等.域外高值医用耗材医保准入制度研究及我国启示[J].上海医药,2021,42(01):65-69.
[2] 国家医疗保障局.医保药品分类与代码数据库更新[EB/OL].(2024-05-24)[2024-06-04].https://code.nhsa.gov.cn/search.html?sysflag=1208.
[3] 国家医疗保障局.医保医用耗材分类与代码数据库更新[EB/OL].(2024-04)[2024-06-04].https://code.nhsa.gov.cn/search.html?sysflag=1202.
[4] 曾叙衡,郑颐,吕军,等.实施高值医用耗材带量采购的SWOT分析——以上海市为例[J].中国卫生政策研究,2020,13(11):37-42.
[5] 陶立波.药品和器械行业应用经济学评价的异同[J].药学与临床研究,2016,24(02):191-192.
[6] 李湘宁,李晓云.人工晶状体的发展趋势及展望[J].光学仪器,2017,39(6):77-83.
[7] 王锡山.随机对照临床试验在外科中的局限性[J].中华结直肠疾病电子杂志,2021,10(05):457-461.
[8] 郑洋洋,丁锦希,李佳明,等.高值耗材实施集中带量采购的主要障碍及对策研究[J].卫生经济研究,2021,38(04):35-38.
[9] 吴瑶,陶立波.医用耗材价值综合评价方法研究进展[J].中国医疗设备,2023,38(10):154-159.
[10] DRUMMOND M, GRIFFIN A, TARRICONE R.Economic evaluation for devices and drugs-same or different?[J].Value in health, 2009, 12(4): 402-404.
[11] 谢春艳,王海银,王美凤,等.基于价值的战略购买:健康中国背景下医保治理的现代化转向[J].中国卫生事业管理,2022,39(05):348-352.
[12] 李珍,陈晋阳,王红波.医保基金战略购买:基本概念、国际经验与中国镜鉴[J].中国卫生政策研究,2021,14(5):1-7.
[13] 丁锦希,李轶,韩晓睿,等.国家医保目录动态调整机制的改革成效与发展思路[J].中国医疗保险,2021(05):40-46.
[14] 国家医疗保障局.医保医用耗材分类与代码数据库更新[EB/OL].(2024-04)[2024-06-04].https://code.nhsa.gov.cn/search.html?sysflag=1202.
[15] 冯珂,郭海科,张英朗,等.多焦点与单焦点散光型人工晶状体植入术后的视功能研究[J].中华眼科杂志,2017,53(4):274-280.
[16] Medtronic.Micra leadless peacemakers for bradycardia[EB/OL].[2024-06-05].https://www.medtronic.com/us-en/patients/treatments-therapies/pacemakers/our/micra.html.
[17] 辽宁省药品和医用耗材集中采购网.公众查询-耗材产品查询[EB/OL].[2024-06-07].http://ggzy.ln.gov.cn/yphc/gzcx/.
[18] 丁锦希,郝丽,潘越,等.医保支付标准与集中采购联动的螺旋式降价效应及其缓冲阈值设计[J].中国医药工业杂志,2018,49(02):239-247.
[19] 厚生劳动省.指定保险医疗物资价格调查[EB/OL].[2024-06-02].https://www.mhlw.go.jp/toukei/list/158-1.html.
[20] 常峰,崔鹏磊,夏强,等.德国药品参考价格体系对构建我国医保支付标准的启示[J].中国卫生政策研究,2015,8(7):55-60.
[21] 厚生劳动省.医疗器械的保险适用范围(预计2021年12月上市)[EB/OL].[2024-06-05].https://www.mhlw.go.jp/content/12404000/000853032.pdf.
[22] FDA.Summary of safety and effectiveness data (SSED)[EB/OL].[2024-06-07].https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190019B.pdf.
[23] 厚生劳动省.医疗器械的保险适用范围(预计2020年9月上市)[EB/OL].(2019-02-08)[2024-06-07].https://www.mhlw.go.jp/content/12404000/000660248.pdf.
[24] GOVINDARAJULU U S, STILLO M, GOLDFARB D, et al.Learning curve estimation in medical devices and procedures: hierarchical modeling[J].Statistics in medicine, 2017, 36(17): 2764-2785.
[25] KUZNIETSOVA V, WOODWARD R S.Estimating the learning curve of a novel medical device: bipolar sealer use in unilateral total knee arthroplasties[J].Value in health, 2018, 21(3): 283-294.